Argent BioPharma (ASX:RGT) executed a further deed of variation with a fund managed by US fund manager Mercer Street Capital Partners for its convertible securities agreement, according to a Wednesday filing with the Australian bourse.
The deed includes refinancing 300,000 convertible notes totaling AU$1.6 million, the filing stated. The companies also agreed to reduce the conversion price to no less than AU$0.30 from at least AU$10.